The Latest Breaking News on Pharma

1 Stock You'll Wish You Bought Sooner

Amid the highly uncertain market conditions, investors must look for stocks with ample room for growth and better stability. Biopharmaceutical major Pfizer’s (PFE) products remain in demand irrespective of economic cycles. Given its robust financials, discounted valuation, and high profitability, it could be wise to invest in this defensive stock.…

StockNews.com · Sep 16, 2022

It's Not Too Late for Investors to Start Buying GILD Stock

Biopharmaceutical giant Gilead Sciences (GILD) has delivered solid segmental sales growth in the last reported quarter. In addition, the company’s various research breakthroughs and drug approvals should further bolster its performance in the coming months. Given its robust profitability and discounted valuation, we think it could be wise to scoop…

StockNews.com · Sep 16, 2022

1 Stock That’ll Make You Turn Blue in the Face for Owning

Biotech company bluebird bio (BLUE) received FDA approval for ZYNTEGLO last month, which seems to have boosted its stock price. However, given its bleak profitability and stretched valuations, the stock might be best avoided. Read on….

StockNews.com · Sep 16, 2022

Pharma services company's shares go up by 12% after it confirms insider dealing probe

Dublin-listed Open Orphan confirmed it is helping gardai in respect of the investigation

Irish Mirror · Sep 15, 2022

This 1 Stock Pays You Just for Owning It

Leading pharmaceutical company Pfizer (PFE) did exceptionally well during the pandemic thanks to the high demand for its COVID-19 vaccine, and it still has enough growth prospects. The company’s focus on strengthening its pipeline via business acquisitions, product development, and approvals is expected to deliver impressive growth in the upcoming…

StockNews.com · Sep 15, 2022

Payment of ₹200 crore to drug companies for supply of Remdesivir in Karnataka stuck due to breach of tender condition

More than a year after the drug was supplied, payments to major pharma companies are stalled due to this violation.

The Hindu · Sep 15, 2022

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…

Benzinga · Sep 14, 2022

The Worst Biotech Stock to Own in September

Biotech stock Ginkgo Bioworks (DNA) has fallen more than 60% year-to-date. The company has been making some acquisitions recently to aid its growth over the next few years. However, given its weak financials and unfavorable analyst estimates, it may not be wise to invest in this stock now. Continue reading….

StockNews.com · Sep 14, 2022

New ALS drug funded by Ice Bucket Challenge already in use in South Florida trials

While the country awaits federal approval of a new ALS drug, people in South Florida with the disease already are using it.

Tribune News Service · Sep 14, 2022

Is the new omicron vaccine worth it?

The omicron-specific booster vaccine hit the market — some wonder if it's worth getting

Salon · Sep 14, 2022